– UK, Glasgow – RUA Life Sciences (LON: RUA), the holding company of a group of medical device businesses focused on the exploitation of the world’s leading long-term implantable biostable polymer, today announced the appointments of Group COO Dr. Caroline Stretton and Ian Ardill to its Board of Directors, effective immediately.
Ian Ardill is joining as a Non-Executive Director and Chair of the Audit Committee
“I am very pleased to welcome Caroline and Ian to the RUA Life Sciences Board. They bring with them significant and diverse experience and will be valuable additions to the Board.” said Board Chairman, Bill Brown.
About Dr. Caroline Stretton
Dr Caroline Stretton who was appointed as Group COO on 1 April 2020, following the acquisition of RUA Medical Devices Limited, joined RUA Medical in 2018 from prosthetic hand manufacturer, Touch Bionics Limited, where, before its sale in 2016 to Icelandic orthotic and prosthetic manufacturer Ossur, she was a key member of the leadership team responsible for Global Manufacturing, Operations, Quality, and Customer Support. Previously, Caroline had been employed by several medical device and pharmaceutical companies in a variety of roles, most notably Ivax Pharmaceuticals, Ocutec Limited, and Mpathy Medical Devices Limited, a surgical medical device company which achieved a multi-million-pound exit to Danish surgical medical device manufacturer, Coloplast, in 2010.
Caroline is a graduate of and holds a Ph.D. in, Pure and Applied Chemistry from, the University of Strathclyde.
About Ian Ardill
Ian Ardill has over 25 years’ experience in senior financial positions, with the majority of that time being spent in medical devices and pharmaceuticals. He is currently Managing Director of Causeway Finance Associates Limited, a CFO and accountancy consultancy focussed in Life Sciences, which he founded in 2017. Previously, he was CFO of Diurnal Limited, which he joined in April 2015 ahead of the successful IPO on AIM in December 2015. Before that, Ian was CFO of two other listed companies. With Lombard Medical Technologies plc, from 2012 to 2015, he led the company financially through the late stages of FDA pre-market approval and the commencement of US commercial operations. On the financing front, he managed a £22 million fundraising on AIM and the company’s IPO on NASDAQ raising $55 million. With Biocompatibles International plc, from 2003 to 2011, he played a leading role in transforming the company from a loss-making to a profitable enterprise with sales of £33 million. He also managed the company’s sale to BTG Plc in 2011 for £177 million and two returns of capital to shareholders totaling £23 million. Ian is a graduate of Warwick University and qualified as a chartered accountant with Grant Thornton.
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group’s four trading businesses, each exploiting the Group’s patented polymer technology.
Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-Eon, the world’s leading long-term implantable polyurethane.
Whether it is licensing Elast-Eon, manufacturing a device or component, or developing next-generation medical devices, and RUA Life Sciences business is pursuing our vision.
Elast-Eon’s biostability is comparable to silicone while exhibiting excellent mechanical, blood-contacting, and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and molding techniques. With over 7 million implants and over 14 years of successful clinical use, RUA’s polymers are proven in long-term life enabling applications.
For more information: https://rualifesciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.